Precision Treatment. Mission-Ready Outcomes.
NRx delivers an integrated neuroscience platform — functional MRI-guided neuronavigation, robotically controlled TMS, and neuroplastic medication — engineered specifically for the operational demands of warfighters and first responders.
Targeting the Invisible Wounds of Service
NRx protocols are designed to address the three most operationally devastating mental health conditions affecting military and first responder populations — with fMRI-guided precision that conventional psychiatry cannot match.
Major Depressive Disorder
4× more prevalent in warfighters vs. civilians
Conventional antidepressants take weeks to act, impair cognitive performance, and carry career-threatening side effects. NRx uses functional MRI to identify the precise prefrontal circuits malfunctioning in each patient's depression, then delivers robotic TMS to drive the creation of new synapses in those exact centers — amplified by FDA-investigational neuroplastic medications that enhance that synaptogenic effect.
NRx Outcomes
- fMRI-identified targeting of the exact malfunctioning brain centers
- Rapid symptom reduction — days, not months
- No cognitive dulling or performance impairment
- No career-threatening medication flags
Post-Traumatic Stress Disorder
30% of combat veterans develop PTSD
PTSD involves dysregulation of specific neural circuits — the amygdala, prefrontal cortex, and hippocampus — that conventional therapy and medication address only indirectly. NRx uses fMRI to map each patient's specific trauma-implicated circuits, then delivers robotic TMS to drive synaptogenesis — the creation of new synaptic connections — in those exact centers, enhanced by FDA-investigational neuroplastic medications.
NRx Outcomes
- fMRI mapping of individual trauma-implicated neural circuits
- Sub-millimeter robotic targeting of identified brain centers
- Reduced hypervigilance and intrusive symptom burden
- Compatible with continued operational duties during treatment
Suicidality & Crisis Intervention
22 veterans lost to suicide every day
Suicidality in warfighters represents a national crisis that conventional care has failed to solve. NRx protocols address the neurobiological underpinnings of suicidal ideation — using fMRI to identify the specific circuits governing emotional regulation and impulse control, then targeting those centers with robotic TMS to drive new synapse creation, enhanced by FDA-investigational neuroplastic medications.
NRx Outcomes
- fMRI identification of circuits governing emotional regulation
- Neurobiological intervention, not symptom suppression
- Rapid reduction in acute suicidal ideation
- Designed for high-acuity military treatment settings
Three Modalities. One Integrated Protocol.
The NRx platform is not a single device or a single drug — it is a precisely engineered sequence of three components that work together: functional MRI identifies the exact malfunctioning brain centers, robotic TMS targets them with sub-millimeter precision, and neuroplastic medication primes the brain to rewire durably.
fMRI Neuronavigation
Functional MRI identifies the precise brain centers that are malfunctioning in each patient's depression or PTSD — not a population average, but that individual's specific neural pathology. The fMRI data is processed into a precision targeting map that guides every subsequent treatment session. This is what separates NRx from conventional TMS: we know exactly where to treat before the first pulse is delivered.
Robotically Controlled TMS
The robotic TMS system uses the fMRI neuronavigation map to deliver precisely targeted magnetic stimulation to the exact brain centers identified as malfunctioning — with sub-millimeter accuracy that manual coil placement cannot achieve. The robotic system eliminates session-to-session variability, ensuring every pulse in every session lands on the intended target. Reproducible. Verifiable. Clinically superior.
Neuroplastic Medication
TMS works by driving the creation of new synapses — new connections — in the brain. NRx protocols pair robotic TMS with FDA-investigational neuroplastic medications that have the potential to enhance this synaptogenic effect. By amplifying the brain's capacity to form new, healthy neural connections, these agents extend the therapeutic reach of each TMS session beyond what stimulation alone can achieve. Their investigational status reflects the cutting edge of neuroscience — not experimental risk, but rigorous clinical development.
From fMRI to Return to Duty
Clinical Assessment
Comprehensive evaluation of the patient's psychiatric history, symptom profile, and operational status — establishing the clinical baseline for fMRI-guided treatment planning.
Functional MRI Brain Mapping
fMRI imaging identifies the precise brain centers that are malfunctioning in this patient's depression or PTSD — producing an individual neural targeting map, not a population average.
Neuroplastic Medication
FDA-investigational neuroplastic medications are initiated alongside TMS — compounds with the potential to enhance the synaptogenic effect of stimulation, amplifying the brain's capacity to form new synaptic connections in the targeted circuits.
Robotic TMS Treatment
The robotic TMS system delivers precisely targeted stimulation to the exact brain centers identified by fMRI — driving the creation of new synapses with sub-millimeter accuracy, session-to-session consistency, and clinically verifiable targeting.
Outcome Verification
Quantitative assessment of neural circuit changes and symptom resolution — providing clinically verifiable evidence of treatment efficacy against the original fMRI baseline.
Return to Duty Clearance
With no antidepressant side effects and no medication flags, personnel are cleared for full operational duty — the outcome the NRx platform is engineered to deliver.
Built for Those Who Carry the Weight
The NRx platform is purpose-built for the populations that carry the highest burden of treatment-resistant PTSD and depression — and face the greatest barriers to conventional care.
Active Duty Military
Deployed and garrison personnel requiring treatment that preserves operational readiness and does not trigger medication-related duty restrictions.
Veterans
Post-service personnel carrying the accumulated neurological burden of combat, operational stress, and moral injury — often undertreated by conventional VA protocols.
Law Enforcement
Officers facing chronic occupational trauma, shift-work stress, and the cumulative neurological impact of high-stakes decision-making under threat.
Firefighters & EMS
First responders with high rates of PTSD and depression driven by repeated exposure to mass casualty events, traumatic loss, and occupational mortality risk.
Clinical Trials Now Enrolling
NRx has been selected and is currently in contracting with DARPA for the SPARC-TMS trial — applying fMRI-guided, robotically controlled TMS to treatment-resistant PTSD and depression in warfighters. View the protocol, eligibility criteria, and submit an enrollment inquiry.
Deploy the NRx Platform at Your Facility
NRx works directly with military treatment facilities, VA systems, and first responder agencies to implement the NRx platform — from clinical assessment through full deployment.